BioInvent International AB - Company Profile
Powered by 
All the data and insights you need on BioInvent International AB in one report.
$295
- Save hours of research time and resources with
our up-to-date BioInvent International AB Strategy Report
- Understand BioInvent International AB position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
BioInvent International AB (BioInvent) focuses on the research and development of antibodies for the treatment of cancer. The company uses n-CoDeR, an inhouse platform for developing immuno-oncology drugs. n-CoDeR is an antibody library used for the rapid selection, screening and identification of antibodies. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin’s lymphoma and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers. It has collaborations and partners with several leading pharmaceutical companies including Pfizer, MSD and Transgene for the co-development of its drug candidates. BioInvent is headquartered in Lund, Sweden.
Headquarters
Sweden
Address
The Gamma Building, Ideongatan 1, Lund, 22370
Website
www.bioinvent.com
Telephone
46 46 2868550
No of Employees
111
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BINV (STO)
Revenue (2022)
$6.7M
-78.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-677.1%
(2022 vs 2021)
Market Cap*
$140.9M
Net Profit Margin (2022)
XYZ
-3,447.4%
(2022 vs 2021)
* As of and is in US$
BioInvent International AB premium industry data and analytics
Products and Services
| Products |
|---|
| BI-1206/rituximab |
| BI-1206/pembrolizumab: Solid Cancer |
| BI-1607: Solid Cancer |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Others | In January, the company received US$3 million equity investment after being selected for the Leukemia & Lymphoma Society’s Therapy Acceleration Program. |
| 2022 | Official Trials/Tests | In December, the company started Phase-I trials for its BI-1206 formulation. |
| 2022 | Patent Grant | In December, the company received notice of allowance for its BI-1206 and BI-1607. |
Competitor Comparison
| Key Parameters | BioInvent International AB | Merck & Co Inc | Pfizer Inc | Bristol-Myers Squibb Co | Amgen Inc |
|---|---|---|---|---|---|
| Headquarters | Sweden | United States of America | United States of America | United States of America | United States of America |
| City | Lund | Kenilworth | New York | Princeton | Thousand Oaks |
| State/Province | - | New Jersey | New York | New Jersey | California |
| No. of Employees | 111 | 72,000 | 88,000 | 34,100 | 26,700 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Leonard Kruimer | Chairman | Executive Board | 2018 | 65 |
| Martin Welschof | Chief Executive Officer | Senior Management | 2018 | 62 |
| Stefan Ericsson | Chief Financial Officer | Senior Management | 2016 | 60 |
| Marie Moores | Chief Operating Officer | Senior Management | 2022 | 55 |
| Andres McAllister, Ph.D. | Chief Medical Officer | Senior Management | 2017 | 67 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward